This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01292655
First received: January 26, 2011
Last updated: May 15, 2017
Last verified: May 2017
  Purpose
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.

Condition Intervention Phase
Cancer Drug: BMS-906024 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Number of subjects with adverse events as a measure of safety and tolerability [ Time Frame: Weekly assessments until study discontinuation due to disease progression or unacceptable adverse event as well as an assessment 30 day after treatment discontinuation with an average time on study expected to be <1 year ]

Secondary Outcome Measures:
  • Tumor assessments using response evaluation criteria in solid tumors (RECIST) v1.1 [ Time Frame: Tumor assessments at least every 8 weeks during treatment period ]
  • PD changes from baseline in the expression of Notch pathway-related genes in surrogate tissues (peripheral blood cells) and tumor biopsies [ Time Frame: PD changes from baseline during the first 4-5 weeks of dosing ]
  • PK parameters for BMS-906024 and its metabolite BMS-911557, maximum observed concentration (Cmax) [ Time Frame: PK at multiple time points during the first 8 weeks of dosing ]
  • PK parameters for BMS-906024 and its metabolite BMS-911557, minimum observed concentration (Cmin) [ Time Frame: PK at multiple time points during the first 8 weeks of dosing ]
  • PK parameters for BMS-906024 and its metabolite BMS-911557, time to reach maximum observed concentration (Tmax) [ Time Frame: PK at multiple time points during the first 8 weeks of dosing ]
  • PK parameters for BMS-906024 and its metabolite BMS-911557, terminal phase elimination half-life (T-Half) [ Time Frame: PK at multiple time points during the first 8 weeks of dosing ]
  • PK parameters for BMS-906024 and its metabolite BMS-911557, accumulation index (AI) [ Time Frame: PK at multiple time points during the first 8 weeks of dosing ]
  • PK parameters for BMS-906024 and its metabolite BMS-911557, area under the concentration-time curve (AUC) [ Time Frame: PK at multiple time points during the first 8 weeks of dosing ]

Estimated Enrollment: 110
Actual Study Start Date: March 3, 2011
Estimated Study Completion Date: June 15, 2017
Estimated Primary Completion Date: June 14, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A1 (Escalation): BMS-906024
BMS-906024 solution intravenously as specified
Drug: BMS-906024
Other Name: BMS-906024 (Notch inhibitor)
Experimental: Arm A2 (Expansion): BMS-906024
BMS-906024 solution intravenously as specified
Drug: BMS-906024
Other Name: BMS-906024 (Notch inhibitor)
Experimental: Arm B1 (Escalation): BMS-906024
BMS-906024 solution intravenously as specified
Drug: BMS-906024
Other Name: BMS-906024 (Notch inhibitor)
Experimental: Arm B2 (Expansion): BMS-906024
BMS-906024 solution intravenously as specified
Drug: BMS-906024
Other Name: BMS-906024 (Notch inhibitor)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

  • Subjects with advanced or metastatic solid tumors (non-hematologic refractory to or relapsed from standard therapies or for which there is no known effective treatment during dose escalation
  • Subjects with squamous non-small cell lung cancer and triple-negative breast cancer or other solid tumor types for which Notch activation has been demonstrated (such as pancreatic, ovarian and melanoma) during dose expansion
  • Biopsy accessible tumor (may be waived under certain circumstances)
  • Life expectancy of at least 3 months
  • Eastern Cooperative Oncology Group (ECOG) 0-1
  • Adequate organ and bone marrow function

Exclusion Criteria:

  • Infection
  • Elevated triglycerides
  • Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel disease (IBD)]
  • Taking medications known to increase risk of Torsades De Pointes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01292655

Locations
United States, California
Anthony El-Khoueiry, Md
Los Angeles, California, United States, 90033
United States, Georgia
Winship Cancer Institute.
Atlanta, Georgia, United States, 30322
United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48201
United States, Mississippi
University Of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
Houston Methodist Hospital
Houston, Texas, United States, 77030
Australia, Victoria
Local Institution
Parkville, Victoria, Australia, 3050
Canada, Ontario
Local Institution
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01292655     History of Changes
Other Study ID Numbers: CA216-001
Study First Received: January 26, 2011
Last Updated: May 15, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

ClinicalTrials.gov processed this record on July 19, 2017